Literature DB >> 22706722

Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer.

Takashi Akiyoshi1, Takashi Kobunai, Toshiaki Watanabe.   

Abstract

Preoperative radiotherapy or chemoradiotherapy (CRT) has become a standard treatment for patients with locally advanced rectal cancer. However, there is a wide spectrum of responses to preoperative CRT, ranging from none to complete. There has been intense interest in the identification of molecular biomarkers to predict the response to preoperative CRT, in order to spare potentially non-responsive patients from unnecessary treatment. However, no specific molecular biomarkers have yet been definitively proven to be predictive of the response to CRT. Instead of focusing on specific factors, microarray-based gene expression profiling technology enables the simultaneous analysis of large numbers of genes, and might therefore have immense potential for predicting the response to preoperative CRT. We herein review published studies using a microarray-based analysis to identify gene expression profiles associated with the response of rectal cancer to radiation or CRT. Although some studies have reported gene expression signatures capable of high predictive accuracy, the compositions of these signatures have differed considerably, with little gene overlap. However, considering the promising data regarding gene profiling in breast cancer, the microarray analysis could still have potential to improve the management of locally advanced rectal cancer. Increasing the number of patients analyzed for more accurate prediction and the extensive validation of predictive classifiers in prospective clinical trials are necessary before such profiling can be incorporated into future clinical practice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22706722     DOI: 10.1007/s00595-012-0223-8

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  56 in total

1.  Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.

Authors:  J-P Machiels; C Sempoux; P Scalliet; J-C Coche; Y Humblet; E Van Cutsem; J Kerger; J-L Canon; M Peeters; S Aydin; S Laurent; A Kartheuser; B Coster; S Roels; J-F Daisne; B Honhon; L Duck; C Kirkove; M-A Bonny; K Haustermans
Journal:  Ann Oncol       Date:  2007-01-05       Impact factor: 32.976

2.  A gene expression signature for chemoradiosensitivity of colorectal cancer cells.

Authors:  Melanie Spitzner; Georg Emons; Frank Kramer; Jochen Gaedcke; Margret Rave-Fränk; Jens-Gerd Scharf; Peter Burfeind; Heinz Becker; Tim Beissbarth; B Michael Ghadimi; Thomas Ried; Marian Grade
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-11-15       Impact factor: 7.038

3.  Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients.

Authors:  Carlo Capirci; Vincenzo Valentini; Luca Cionini; Antonino De Paoli; Claus Rodel; Robert Glynne-Jones; Claudio Coco; Mario Romano; Giovanna Mantello; Silvia Palazzi; Falchetti Osti Mattia; Maria Luisa Friso; Domenico Genovesi; Cristiana Vidali; Maria Antonietta Gambacorta; Alberto Buffoli; Marco Lupattelli; Maria Silvia Favretto; Giuseppe La Torre
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-11       Impact factor: 7.038

4.  Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy.

Authors:  B Michael Ghadimi; Marian Grade; Michael J Difilippantonio; Sudhir Varma; Richard Simon; Cristina Montagna; Laszlo Füzesi; Claus Langer; Heinz Becker; Torsten Liersch; Thomas Ried
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

5.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.

Authors:  Claus Rödel; Peter Martus; Thomas Papadoupolos; Laszlo Füzesi; Martin Klimpfinger; Rainer Fietkau; Torsten Liersch; Werner Hohenberger; Rudolf Raab; Rolf Sauer; Christian Wittekind
Journal:  J Clin Oncol       Date:  2005-10-24       Impact factor: 44.544

6.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

7.  Genetic markers predictive of response to induction chemoradiotherapy for locally advanced rectal cancers.

Authors:  Mahesh Kudrimoti; Eun Young Lee; Yuna Kang; Mansoor Ahmed; Mohammed Mohiuddin
Journal:  J Ky Med Assoc       Date:  2007-01

8.  Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer.

Authors:  Caroline Rimkus; Jan Friederichs; Anne-Laure Boulesteix; Jörg Theisen; Jörg Mages; Karen Becker; Hjalmar Nekarda; Robert Rosenberg; Klaus-Peter Janssen; Jörg Rüdiger Siewert
Journal:  Clin Gastroenterol Hepatol       Date:  2008-01       Impact factor: 11.382

Review 9.  Recent approaches to identifying biomarkers for high-risk stage II colon cancer.

Authors:  Takashi Akiyoshi; Takashi Kobunai; Toshiaki Watanabe
Journal:  Surg Today       Date:  2012-09-09       Impact factor: 2.549

10.  Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors.

Authors:  Karen-Lise G Spindler; Jens N Nielsen; Jan Lindebjerg; Anders Jakobsen
Journal:  Dis Colon Rectum       Date:  2007-09       Impact factor: 4.585

View more
  21 in total

Review 1.  Molecular Biology: Are We Getting Any Closer to Providing Clinically Useful Information?

Authors:  Georgios Karagkounis; Matthew F Kalady
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

2.  Impact of second-line and later cetuximab-containing therapy and KRAS genotypes in patients with metastatic colorectal cancer: a multicenter study in Japan.

Authors:  Hiroshi Saeki; Yasunori Emi; Ryuichi Kumashiro; Hajime Otsu; Hiroyuki Kawano; Koji Ando; Satoshi Ida; Yasue Kimura; Eriko Tokunaga; Eiji Oki; Masaru Morita; Mototsugu Shimokawa; Yoshihiko Maehara
Journal:  Surg Today       Date:  2013-09-08       Impact factor: 2.549

3.  Impact of the post/preoperative serum CEA ratio on the survival of patients with rectal cancer.

Authors:  Tsukasa Hotta; Katsunari Takifuji; Shozo Yokoyama; Kenji Matsuda; Yoshimasa Oku; Toru Nasu; Junji Ieda; Naoyuki Yamamoto; Hiromitsu Iwamoto; Yoh Takei; Yuki Mizumoto; Hiroki Yamaue
Journal:  Surg Today       Date:  2014-02-07       Impact factor: 2.549

4.  The surgeon and molecular knowledge.

Authors:  Ravi Kant; Bina Ravi
Journal:  Indian J Surg       Date:  2013-06       Impact factor: 0.656

Review 5.  Clinical utility of pretreatment prediction of chemoradiotherapy response in rectal cancer: a review.

Authors:  Byong Chul Yoo; Seung-Gu Yeo
Journal:  EPMA J       Date:  2017-03-03       Impact factor: 6.543

6.  Early dynamic transcriptomic changes during preoperative radiotherapy in patients with rectal cancer: a feasibility study.

Authors:  Stephane Supiot; Wilfried Gouraud; Loïc Campion; Pascal Jezéquel; Bruno Buecher; Josiane Charrier; Marie-Francoise Heymann; Marc-Andre Mahé; Emmanuel Rio; Michel Chérel
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

7.  Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer.

Authors:  Theodore S Hong; Eliezer M Van Allen; Sophia C Kamran; Jochen K Lennerz; Claire A Margolis; David Liu; Brendan Reardon; Stephanie A Wankowicz; Emily E Van Seventer; Adam Tracy; Jennifer Y Wo; Scott L Carter; Henning Willers; Ryan B Corcoran
Journal:  Clin Cancer Res       Date:  2019-06-28       Impact factor: 12.531

8.  Quantitative imaging outperforms molecular markers when predicting response to chemoradiotherapy for rectal cancer.

Authors:  Ines Joye; Annelies Debucquoy; Christophe M Deroose; Vincent Vandecaveye; Eric Van Cutsem; Albert Wolthuis; André D'Hoore; Xavier Sagaert; Mu Zhou; Olivier Gevaert; Karin Haustermans
Journal:  Radiother Oncol       Date:  2017-06-21       Impact factor: 6.280

9.  Genomic variation as a marker of response to neoadjuvant therapy in locally advanced rectal cancer.

Authors:  Jason K Douglas; Rose E Callahan; Zachary A Hothem; Craig S Cousineau; Samer Kawak; Bryan J Thibodeau; Shelli Bergeron; Wei Li; Claire E Peeples; Harry J Wasvary
Journal:  Mol Cell Oncol       Date:  2020-03-02

10.  Future directions in combined modality therapy for rectal cancer: reevaluating the role of total mesorectal excision after chemoradiotherapy.

Authors:  Abhishek A Solanki; Daniel T Chang; Stanley L Liauw
Journal:  Onco Targets Ther       Date:  2013-08-14       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.